The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.

Merck (MRK) stock in focus as the company urges shareholders to reject a mini-tender offer which stands at a 25% discount to ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that Tutanota LLC (Tutanota) has ...

Merck has bullish valuation metrics and is trading above its 30-week EMA with bullish long-term momentum. Learn why MRK stock ...

Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

Are you wondering if Merck KGaA is undervalued, overvalued, or finally priced just right? Let's demystify the numbers together and see if there's opportunity hiding beneath the surface. Despite its ...

Many healthcare companies operate in mature and stable industries with a history of profitability. This can be an incredibly ...

Merck & Co. Inc. (NYSE: MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ: CDTX) for $221.50 per share in ...

Merck’s MRK shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though ...

Antipodes Partners recently published its “Antipodes Global Value Strategy” third-quarter 2025 investor letter, highlighting ...

Merck has agreed to acquire Cidara Therapeutics, a biotech company developing a drug designed to prevent the flu.